Plasma neutrophil gelatinase-associated lipocalin (NGAL) concentration of living liver transplant recipients according to the albumin administration during surgery: prospective, randomized control trial
Not Applicable
Recruiting
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0007760
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 318
Inclusion Criteria
Adult recipients (>= 19)
Patients with preoperative creatinine level < 2.0 mg/dl
Exclusion Criteria
chronic kidney disease
preoperative renal replacement therapy
liver-kidney transplantation candidate
kidney transplant recipients
hepatorenal syndrome
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method GAL level
- Secondary Outcome Measures
Name Time Method GAL level;creatinine;albumin level;Postoperative acute kidney injury;Postoperative pulmonary edema assessed by chest roenterogram;Graft failure;Readmission;mortality;Blood biomarker for ischemic reperfusion injury ;peak AST and ALT;Surgical complication assessed with Clavien-Dindo classification
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link albumin administration to NGAL levels in liver transplant recipients?
How does perioperative albumin compare to standard fluids in preventing renal injury post-liver transplant?
Can plasma NGAL serve as a predictive biomarker for acute kidney injury in living liver donors?
What adverse events are associated with high-dose albumin during liver transplantation and how are they managed?
Are there alternative colloids or combination therapies that modulate NGAL expression in hepatic surgery?